Modulation of Visually Evoked Potentials by an Antidepressant

This study has been completed.
Sponsor:
Information provided by:
University Hospital Freiburg
ClinicalTrials.gov Identifier:
NCT00263133
First received: December 6, 2005
Last updated: June 1, 2007
Last verified: May 2007
  Purpose

12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.


Condition Intervention
Depression
Drug: Sertraline

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Modulation of Visually Evoked Potentials by an Antidepressant

Resource links provided by NLM:


Further study details as provided by University Hospital Freiburg:

Primary Outcome Measures:
  • Amplitudes and latencies of early visually evoked potentials.

Estimated Enrollment: 12
Study Start Date: December 2005
Estimated Study Completion Date: January 2006
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy individuals 18-65 years

Exclusion Criteria:

  • history of affective oder other psyhiatric disorder
  • severe medical condition
  • pregnancy or ineffective contraception
  • active illicit drug use
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263133

Locations
Germany
Dept. of Psychiatry, University of Freiburg
Freiburg, Germany, 79104
Sponsors and Collaborators
University Hospital Freiburg
Investigators
Principal Investigator: Claus Normann, MD Dept. of Psychiatry, University of Freiburg
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00263133     History of Changes
Other Study ID Numbers: VEP-1, EudraCT 2005-005417-37
Study First Received: December 6, 2005
Last Updated: June 1, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Freiburg:
Depression
SSRI
Sertraline
synaptic plasticity
visually evoked potentials

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Sertraline
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 20, 2014